Covid rebound could have different causes

Embargoed until: Publicly released: 2024-03-14 02:00

International

PHOTO: CDC/Unsplash

Chinese researchers studied Covid rebound rates after people with mild or moderate Covid took either Paxlovid or a new kind of antiviral called VV116. In both cases, roughly one out of every five patients saw their viral loads bounce back, and a roughly one in four had symptoms return. However, a rebound in viral loads didn’t necessarily mean someone would feel their Covid symptoms return, and vice versa. The author team says symptom rebound could have several other causes, and that viral and symptom rebound might be distinct features that can occur in people with mild to moderate Covid-19.

Media release

From:

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: National Clinical Research Center for Metabolic Diseases, China; See PDF for full list of author affiliations

Funder: This work was supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (grant 2017ZX09304007), the National Natural Science Foundation of China (grants 82088102 and 81970728), the Science and Technology Commission of Shanghai Municipality (grants 22Y31900300 and 23XD1432600), and the Innovative Research Team of High-Level Local Universities in Shanghai. Dr Yu Xu is supported by the National Top Young Talents program. VV116 and nirmatrelvir–ritonavir tablets were provided by the Shanghai Junshi Biosciences Co Ltd.

Media Contact/s

Contact details are only visible to registered journalists.